Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infectious diseases of poverty 2017-01, Vol.6 (1), p.7-7, Article 7
Hauptverfasser: Kibret, Kelemu Tilahun, Moges, Yonatan, Memiah, Peter, Biadgilign, Sibhatu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue 1
container_start_page 7
container_title Infectious diseases of poverty
container_volume 6
creator Kibret, Kelemu Tilahun
Moges, Yonatan
Memiah, Peter
Biadgilign, Sibhatu
description Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus. A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran's Q test and I statistic. Pooled estimates of treatment outcomes were computed using the random effect model. Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4-68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0-16.2%) of the patients died, 14.2% (95% CI: 11.6-16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6-9.7%) failed therapy. Overall 35.4% (95% CI: 30-40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32-54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens. This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.
doi_str_mv 10.1186/s40249-016-0214-x
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5240443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477785636</galeid><sourcerecordid>A477785636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-34ccaf9293ac1eb2d3cb5344d62fe8fef094db1af03a58d3418d7359864b291a3</originalsourceid><addsrcrecordid>eNptkktv1DAUhSMEolXpD2CDLCGhblLs2E4cFkhVKQ-pUpEY1pZj38y4cuLiR-ms-8fxMKXMIOyFrZvvHNs3p6peEnxKiGjfRoYb1teYtDVuCKvvnlSHDS6Vvufd0539QXUc4zUuQwhGGHleHTQC9xR34rC6XwRQaYI5IZ-T9hNENPqApuySNSEv6wDRxqQKkPIAQWfnSwHl2UBAH64W3-qvLsd3SKG4jgkmlaxGAW4t_ERqNmiCpGo1K7feyPyIbvLgbFyBQTFlYyG-qJ6NykU4fliPqu8fLxbnn-vLq09fzs8ua80bnmrKtFZj3_RUaQJDY6geOGXMtM0IYoQR98wMRI2YKi4MZUSYjvJetGxoeqLoUfV-61tuMIHR5dFBOXkT7KTCWnpl5f6X2a7k0t9K3jDMGC0GJw8Gwf_IEJOcbNTgnJrB5yjLbyGcUcE36Ot_0GufQ-nCb4o3uKUM_6WWyoG08-jLuXpjKs9Y13WCt7Qt1Ol_qDINTFb7GUZb6nuCNzuCFSiXVtG7nKyf4z5ItqAOPsYA42MzCJablMltymRJmdykTN4VzavdLj4q_mSK_gLMq88G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1865206340</pqid></control><display><type>article</type><title>Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kibret, Kelemu Tilahun ; Moges, Yonatan ; Memiah, Peter ; Biadgilign, Sibhatu</creator><creatorcontrib>Kibret, Kelemu Tilahun ; Moges, Yonatan ; Memiah, Peter ; Biadgilign, Sibhatu</creatorcontrib><description>Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus. A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran's Q test and I statistic. Pooled estimates of treatment outcomes were computed using the random effect model. Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4-68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0-16.2%) of the patients died, 14.2% (95% CI: 11.6-16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6-9.7%) failed therapy. Overall 35.4% (95% CI: 30-40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32-54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens. This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.</description><identifier>ISSN: 2049-9957</identifier><identifier>ISSN: 2095-5162</identifier><identifier>EISSN: 2049-9957</identifier><identifier>DOI: 10.1186/s40249-016-0214-x</identifier><identifier>PMID: 28093078</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Care and treatment ; Directly Observed Therapy ; Drug resistance in microorganisms ; Humans ; Mycobacterium tuberculosis - drug effects ; Patient outcomes ; Treatment Outcome ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>Infectious diseases of poverty, 2017-01, Vol.6 (1), p.7-7, Article 7</ispartof><rights>COPYRIGHT 2017 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2017</rights><rights>The Author(s). 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-34ccaf9293ac1eb2d3cb5344d62fe8fef094db1af03a58d3418d7359864b291a3</citedby><cites>FETCH-LOGICAL-c525t-34ccaf9293ac1eb2d3cb5344d62fe8fef094db1af03a58d3418d7359864b291a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240443/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240443/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28093078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kibret, Kelemu Tilahun</creatorcontrib><creatorcontrib>Moges, Yonatan</creatorcontrib><creatorcontrib>Memiah, Peter</creatorcontrib><creatorcontrib>Biadgilign, Sibhatu</creatorcontrib><title>Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies</title><title>Infectious diseases of poverty</title><addtitle>Infect Dis Poverty</addtitle><description>Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus. A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran's Q test and I statistic. Pooled estimates of treatment outcomes were computed using the random effect model. Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4-68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0-16.2%) of the patients died, 14.2% (95% CI: 11.6-16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6-9.7%) failed therapy. Overall 35.4% (95% CI: 30-40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32-54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens. This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.</description><subject>Analysis</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Care and treatment</subject><subject>Directly Observed Therapy</subject><subject>Drug resistance in microorganisms</subject><subject>Humans</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Patient outcomes</subject><subject>Treatment Outcome</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>2049-9957</issn><issn>2095-5162</issn><issn>2049-9957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkktv1DAUhSMEolXpD2CDLCGhblLs2E4cFkhVKQ-pUpEY1pZj38y4cuLiR-ms-8fxMKXMIOyFrZvvHNs3p6peEnxKiGjfRoYb1teYtDVuCKvvnlSHDS6Vvufd0539QXUc4zUuQwhGGHleHTQC9xR34rC6XwRQaYI5IZ-T9hNENPqApuySNSEv6wDRxqQKkPIAQWfnSwHl2UBAH64W3-qvLsd3SKG4jgkmlaxGAW4t_ERqNmiCpGo1K7feyPyIbvLgbFyBQTFlYyG-qJ6NykU4fliPqu8fLxbnn-vLq09fzs8ua80bnmrKtFZj3_RUaQJDY6geOGXMtM0IYoQR98wMRI2YKi4MZUSYjvJetGxoeqLoUfV-61tuMIHR5dFBOXkT7KTCWnpl5f6X2a7k0t9K3jDMGC0GJw8Gwf_IEJOcbNTgnJrB5yjLbyGcUcE36Ot_0GufQ-nCb4o3uKUM_6WWyoG08-jLuXpjKs9Y13WCt7Qt1Ol_qDINTFb7GUZb6nuCNzuCFSiXVtG7nKyf4z5ItqAOPsYA42MzCJablMltymRJmdykTN4VzavdLj4q_mSK_gLMq88G</recordid><startdate>20170117</startdate><enddate>20170117</enddate><creator>Kibret, Kelemu Tilahun</creator><creator>Moges, Yonatan</creator><creator>Memiah, Peter</creator><creator>Biadgilign, Sibhatu</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170117</creationdate><title>Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies</title><author>Kibret, Kelemu Tilahun ; Moges, Yonatan ; Memiah, Peter ; Biadgilign, Sibhatu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-34ccaf9293ac1eb2d3cb5344d62fe8fef094db1af03a58d3418d7359864b291a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Analysis</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Care and treatment</topic><topic>Directly Observed Therapy</topic><topic>Drug resistance in microorganisms</topic><topic>Humans</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Patient outcomes</topic><topic>Treatment Outcome</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kibret, Kelemu Tilahun</creatorcontrib><creatorcontrib>Moges, Yonatan</creatorcontrib><creatorcontrib>Memiah, Peter</creatorcontrib><creatorcontrib>Biadgilign, Sibhatu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infectious diseases of poverty</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kibret, Kelemu Tilahun</au><au>Moges, Yonatan</au><au>Memiah, Peter</au><au>Biadgilign, Sibhatu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies</atitle><jtitle>Infectious diseases of poverty</jtitle><addtitle>Infect Dis Poverty</addtitle><date>2017-01-17</date><risdate>2017</risdate><volume>6</volume><issue>1</issue><spage>7</spage><epage>7</epage><pages>7-7</pages><artnum>7</artnum><issn>2049-9957</issn><issn>2095-5162</issn><eissn>2049-9957</eissn><abstract>Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus. A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran's Q test and I statistic. Pooled estimates of treatment outcomes were computed using the random effect model. Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4-68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0-16.2%) of the patients died, 14.2% (95% CI: 11.6-16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6-9.7%) failed therapy. Overall 35.4% (95% CI: 30-40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32-54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens. This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>28093078</pmid><doi>10.1186/s40249-016-0214-x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-9957
ispartof Infectious diseases of poverty, 2017-01, Vol.6 (1), p.7-7, Article 7
issn 2049-9957
2095-5162
2049-9957
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5240443
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Springer Nature OA Free Journals; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Analysis
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Care and treatment
Directly Observed Therapy
Drug resistance in microorganisms
Humans
Mycobacterium tuberculosis - drug effects
Patient outcomes
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
title Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20outcomes%20for%20multidrug-resistant%20tuberculosis%20under%20DOTS-Plus:%20a%20systematic%20review%20and%20meta-analysis%20of%20published%20studies&rft.jtitle=Infectious%20diseases%20of%20poverty&rft.au=Kibret,%20Kelemu%20Tilahun&rft.date=2017-01-17&rft.volume=6&rft.issue=1&rft.spage=7&rft.epage=7&rft.pages=7-7&rft.artnum=7&rft.issn=2049-9957&rft.eissn=2049-9957&rft_id=info:doi/10.1186/s40249-016-0214-x&rft_dat=%3Cgale_pubme%3EA477785636%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1865206340&rft_id=info:pmid/28093078&rft_galeid=A477785636&rfr_iscdi=true